Multicenter randomized trial of adjuvant temozolomide with or without interferon alfa for newly diagnosed high-grade glioma
Prof. Zhongping Chen
High-grade gliomas constitute the most common and aggressive primary brain tumor, with 5-year survival rates of 30.9% for grade 3 gliomas and 6.6% for grade 4 gliomas. A multicenter randomized study in China found that after surgery for newly diagnosed high-grade glioma, addition of interferon alfa to the standard regimen of radiotherapy plus temozolomide was associated with prolonged survival, while the toxic effects remained tolerable.
